1BMK

THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.189 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Structural basis of inhibitor selectivity in MAP kinases.

Wang, Z.Canagarajah, B.J.Boehm, J.C.Kassisa, S.Cobb, M.H.Young, P.R.Abdel-Meguid, S.Adams, J.L.Goldsmith, E.J.

(1998) Structure 6: 1117-1128

  • Primary Citation of Related Structures:  1A9U, 1BL6, 1BL7, 3ERK, 4ERK

  • PubMed Abstract: 
  • The mitogen-activated protein (MAP) kinases are important signaling molecules that participate in diverse cellular events and are potential targets for intervention in inflammation, cancer, and other diseases. The MAP kinase p38 is responsive to envi ...

    The mitogen-activated protein (MAP) kinases are important signaling molecules that participate in diverse cellular events and are potential targets for intervention in inflammation, cancer, and other diseases. The MAP kinase p38 is responsive to environmental stresses and is involved in the production of cytokines during inflammation. In contrast, the activation of the MAP kinase ERK2 (extracellular-signal-regulated kinase 2) leads to cellular differentiation or proliferation. The anti-inflammatory agent pyridinylimidazole and its analogs (SB [SmithKline Beecham] compounds) are highly potent and selective inhibitors of p38, but not of the closely-related ERK2, or other serine/threonine kinases. Although these compounds are known to bind to the ATP-binding site, the origin of the inhibitory specificity toward p38 is not clear.


    Related Citations: 
    • A Map Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian Cells
      Han, J.,Lee, J.D.,Bibbs, L.,Ulevitch, R.J.
      (1994) Science 265: 808
    • A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis
      Lee, J.C.,Laydon, J.T.,Mcdonnell, P.C.,Gallagher, T.F.,Kumar, S.,Green, D.,Mcnulty, D.,Blumenthal, M.J.,Heys, J.R.,Landvatter, S.W.,Strickler, J.E.,Mclaughlin, M.M.,Siemens, I.R.,Fisher, S.M.,Livi, G.P.,White, J.R.,Adams, J.L.,Young, P.R.
      (1994) Nature 372: 739
    • Pro-Inflammatory Cytokines and Environmental Stress Cause P38 Mitogen- Activated Protein Kinase Activation by Dual Phosphorylation on Tyrosine and Threonine
      Raingeaud, J.,Gupta, S.,Rogers, J.S.,Dickens, M.,Han, J.,Ulevitch, R.J.,Davis, R.J.
      (1995) J.Biol.Chem. 270: 7420


    Organizational Affiliation

    Department of Biochemistry The University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Boulevard, Dallas, TX 75235, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
PROTEIN (MAP KINASE P38)
A
379Homo sapiensGene Names: MAPK14 (CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A)
EC: 2.7.11.24
Find proteins for Q16539 (Homo sapiens)
Go to Gene View: MAPK14
Go to UniProtKB:  Q16539
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SB5
Query on SB5

Download SDF File 
Download CCD File 
A
4-(FLUOROPHENYL)-1-CYCLOPROPYLMETHYL-5-(2-AMINO-4-PYRIMIDINYL)IMIDAZOLE
C17 H16 F N5
DFEYXQGDDCDXJK-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
SB5IC50: 25 nM (99) BINDINGDB
SB5IC50: 25 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.189 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 45.580α = 90.00
b = 85.220β = 90.00
c = 123.500γ = 90.00
Software Package:
Software NamePurpose
X-PLORrefinement
AMoREphasing
SCALEPACKdata scaling
DENZOdata reduction
CCP4phasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 1999-07-23
    Type: Initial release
  • Version 1.1: 2008-04-27
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance
  • Version 1.3: 2017-02-01
    Type: Structure summary